ClearPoint Neuro Inc 2025年季度报告

For the quarterly period endedMarch 31,2025 Commission file number:001-34822 of Incorporation or Organization) “Quarterly Report”) are the property of their respective owners. Balances, March 31, 202527,980,184$280$217,103$(197,396)$ Common Stock 24,652,729 See accompanying notes to Condensed Consolidated Financial Statements. 3 For the Three Months Ended March31,20252024Cash flows from operating activities:$(6,026)$Adjustments to reconcile net loss to net cash flows from operating activities:Allowance for credit losses (recoveries)217 Inventory, netPrepaid expenses and other current assets Other assets—Accounts payable and accrued expenses(2,882)Lease liabilities(234)Contract liabilities(581)Net cash flows from operating activities(6,172)Cash flows from investing activities: Payments for taxes related to net share settlement of equity awardsNet cash flows from financing activitiesNet change in cash and cash equivalents SUPPLEMENTAL CASH FLOW INFORMATIONCash paid for:Income taxes$—$$—$ having an aggregate net book value of$0.2millionbetween loaned systems, which are included in property and equipmentin the accompanying condensed consolidated balance sheets, and inventory. The balance of such transfers during the threemonths ended March 31, 2024 was nominal. See accompanying notes to Condensed Consolidated Financial Statements. Description of the Business and Financial ConditionClearPoint Neuro, Inc. (the “Company”) is a commercial-stage medical device company focused on the development andcommercialization of innovative platforms for performing minimally invasive surgical procedures in the brain. From theCompany’s inception in 1998, the Company has deployed significant resources to fund its efforts to develop the capabilities forenabling neurosurgery interventions, building an intellectual property portfolio, and identifying and building out commercialapplications for the technologies it develops. In 2021, the Company’s efforts expanded beyond the MRI suite to encompassdevelopment and commercialization of new neurosurgical device products for the operating room setting. In 2022, the Companycommercialized the ClearPoint Prism Neuro Laser Therapy System as its first therapy product offering.The Company has evaluating or using its products and services in trials to inject gene and cell therapies directly into the brain. These relationshipsinvolve drug development programs that are at various stages of development ranging from preclinical research to late-stage regulatory trials for multiple distinct disease states. This part of the Company’s business potentially represents the largestopportunity for growth; however, the Company’s ability to grow in this market is dependent on its ability to maintain and establishnew relationships with customers, such customers' continuation of research and product development plans, and such customers'achievement of success in completion of clinical trials and subsequent regulatory approvals of their biologics and drugs. willingness to spend on the Company’s products and services, or their ability to make payments, which could harm the collectionof accounts receivable and financial results. The world’s financial markets remain susceptible to significant stresses, resulting in situations precludes any prediction as to the ultimate impact they will have on the Company’s business, financial condition, resultsof operation and cash flows, which will depend largely on future developments. LiquidityThe Company has incurred net losses since its inception, which has resulted in a cumulative deficit at March 31, 2025 of$197.4million. In addition, the Company’s use of cash from operations amounted to$6.2millionfor the three months ended March 31, by generally accepted accounting principles in the U.S. (“GAAP”), the Company has evaluated its ability to continue as a goingconcern and has determined that based on current forecasts, existing cash and cash equivalent balances at March 31, 2025 aresufficient to support the Company's operations and meet its obligations for at least the next twelve months. In March 2024, the Company completed a follow-on public offering of2,653,848shares of its common stock from which the netproceeds totaled approximately $16.2 million after deducting underwriting discounts and commissions, and other offeringexpenses paid by the Company. In November 2024, the Company entered into an At-the-Market Equity Offering Sales Agreementwith an investment banking firm (the “ATM Agreement”) pursuant to which it may offer and sell, from time to time, shares of itscommon stock, having aggregate sales proceeds of up to $50million, subject to the terms and conditions of the ATM Agreement.ThroughMarch 31, 2025, the Company hadnot issued any shares of common stock under the ATM Agreement. See Note 8 belowfor additional information with respect to these offerings. Basis of Presentation and Use of Estimates basis consistent with the Company’s December 31,